Notice of Allowance

CERULEAN

Cerulean Pharma Inc.

Notice of Allowance

Corrected Aug 10, 2012
U.S. Patent and Trademark Office (USPTO) NOTICE OF ALLOWANCE

NOTE: If any data on this notice is incorrect, please fax a request for correction to the Intent to Use Unit at 571-273-9550. Please include the serial number of your application on ALL correspondence with the USPTO.

ISSUE DATE: May 15, 2012

DAVID EHRLICH
FROSS ZELNICK LEHRMAN & ZISSU, P.C.
866 UNITED NATIONS PLZ
NEW YORK, NY 10017-1822

ATTORNEY
REFERENCE NUMBER

TPHA 1104692

** IMPORTANT INFORMATION: 6 MONTH DEADLINE **

You filed the trademark application identified below based upon a bona fide intention to use the mark in commerce. You must use the mark in commerce and file a Statement of Use (a.k.a. Allegation of Use) before the USPTO will register the mark. You have six (6) MONTHS from the ISSUE DATE of this Notice of Allowance (NOA) to file either a Statement of Use, or if you are not yet using the mark in commerce, a Request for Extension of Time to File a Statement of Use ("Extension Request"). If you file an extension request, you must continue to file a new request every six months calculated from the issue date of the NOA until the Statement of Use is filed. Applicant may file a total of five (5) extension requests. FAILURE TO FILE A REQUIRED DOCUMENT DURING THE APPROPRIATE TIME PERIOD WILL RESULT IN THE ABANDONMENT OF YOUR APPLICATION.

Please note that both the "Statement of Use " and "Extension Request" have many legal requirements including fees. Therefore, we encourage use of the USPTO forms, available online at http://www.gov.uspto.report/teas/index.html (under "INTENT-TO-USE (ITU) FORMS"), to avoid the possible omission of important information. Please note that the Trademark Electronic Application System (TEAS) provides line-by-line help instructions for completing the Extension Request or Statement of Use forms online. If you do not have access to the Internet, you may call 1-800-786-9199 to request the printed form(s).

** Registration Subject to Cancellation for Fraudulent Statements **

Ensure that statements made in filings to the USPTO are accurate, as inaccuracies may result in the cancellation of your trademark registration. The lack of a bona fide intention to use the mark with all goods and/or services included in an application or the lack of use on all goods and/or services for which you claimed use could jeopardize the validity of your registration, possibly resulting in its cancellation.

The following information should be reviewed for accuracy:

SERIAL NUMBER:	85/442528
MARK:	CERULEAN (STANDARD CHARACTER MARK)
OWNER:	Cerulean Pharma Inc. 840 Memorial Drive, 5th Floor Cambridge , MASSACHUSETTS 02139

This application has the following bases, but not necessarily for all listed goods/services:

Section 1(a): NO

Section 1(b): YES

Section 44(e): NO

GOODS/SERVICES BY INTERNATIONAL CLASS

005 -

pharmaceutical preparations for use in the diagnosis, prognosis or prevention of oncological diseases or disorders, including malignant cancers or neoplasms; pharmaceutical preparations for use in the diagnosis, prognosis, prevention or treatment of oncological diseases or disorders, including pre-cancerous diseases or disorders and benign cancers or neoplasms, inflammation and inflammatory diseases or disorders, and cardiovascular diseases or disorders; pharmaceutical preparations for use in modulating angiogenesis; pharmaceutical preparations for use in the diagnosis, prognosis and prevention of oncological diseases or disorders, including malignant cancers or neoplasms, all containing nanometer size compounds which facilitate targeting or delivery of the active ingredient; pharmaceutical preparations for use in the diagnosis, prognosis, prevention or treatment of oncological diseases or disorders, including pre-cancerous diseases or disorders and benign cancers or neoplasms, inflammation and inflammatory diseases or disorders, and cardiovascular diseases or disorders, all containing nanometer size compounds which facilitate targeting or delivery of the active ingredient; pharmaceutical preparations for use in modulating angiogenesis, containing nanometer size compounds which facilitate targeting or delivery of the active ingredient -- FIRST USE DATE: NONE; -- USE IN COMMERCE DATE: NONE

ALL OF THE GOODS/SERVICES IN EACH CLASS ARE LISTED

ADDITIONAL INFORMATION MAY BE PRESENT IN THE USPTO RECORDS

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.